JP2017502983A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502983A5
JP2017502983A5 JP2016546192A JP2016546192A JP2017502983A5 JP 2017502983 A5 JP2017502983 A5 JP 2017502983A5 JP 2016546192 A JP2016546192 A JP 2016546192A JP 2016546192 A JP2016546192 A JP 2016546192A JP 2017502983 A5 JP2017502983 A5 JP 2017502983A5
Authority
JP
Japan
Prior art keywords
patient
treatment
disease state
composition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502983A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2014/050870 external-priority patent/WO2015049688A2/en
Publication of JP2017502983A publication Critical patent/JP2017502983A/ja
Publication of JP2017502983A5 publication Critical patent/JP2017502983A5/ja
Pending legal-status Critical Current

Links

JP2016546192A 2013-10-02 2014-10-02 不均一な腫瘍を処置するための患者特異的免疫療法 Pending JP2017502983A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361885511P 2013-10-02 2013-10-02
US61/885,511 2013-10-02
PCT/IL2014/050870 WO2015049688A2 (en) 2013-10-02 2014-10-02 Patient-specific immunotherapy for treating heterogeneous tumors

Publications (2)

Publication Number Publication Date
JP2017502983A JP2017502983A (ja) 2017-01-26
JP2017502983A5 true JP2017502983A5 (https=) 2018-08-16

Family

ID=52779242

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016546192A Pending JP2017502983A (ja) 2013-10-02 2014-10-02 不均一な腫瘍を処置するための患者特異的免疫療法
JP2017517721A Pending JP2018500275A (ja) 2013-10-02 2015-04-08 不均一な腫瘍を処置するための患者特異的免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017517721A Pending JP2018500275A (ja) 2013-10-02 2015-04-08 不均一な腫瘍を処置するための患者特異的免疫療法

Country Status (5)

Country Link
US (2) US20160237163A1 (https=)
EP (2) EP3052933B1 (https=)
JP (2) JP2017502983A (https=)
CN (2) CN106133521A (https=)
WO (2) WO2015049688A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113391A2 (en) * 2012-02-02 2013-08-08 Brainlab Ag Method for determining an infusion parameter
US20160237163A1 (en) * 2013-10-02 2016-08-18 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors
WO2016187711A1 (en) * 2015-05-22 2016-12-01 Csts Health Care Inc. Biomarker-driven molecularly targeted combination therapies based on knowledge representation pathway analysis
EP3298524A4 (en) 2015-05-22 2019-03-20 CSTS Health Care Inc. THERMODYNAMIC MEASURES ON PROTEIN-PROTEIN INTERACTION NETWORKS FOR CANCER THERAPY
AU2016339022B2 (en) * 2015-10-12 2020-09-10 Nantomics, Llc Iterative discovery of neoepitopes and adaptive immunotherapy and methods therefor
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CA3026236C (en) * 2016-06-03 2021-01-26 Samsung Life Public Welfare Foundation Method for screening antibody using patient-derived tumor spheroids
US12072337B2 (en) 2017-05-30 2024-08-27 Nant Holdings Ip, Llc Circulating tumor cell enrichment using neoepitopes
WO2019156254A1 (ja) * 2018-02-09 2019-08-15 アクシオンリサーチ株式会社 検査対象の複雑系の状態を推定するシステム
CN113597305B (zh) * 2019-03-15 2025-03-04 舒万诺知识产权公司 使用因果模型制造生物药物
US20220268762A1 (en) * 2019-07-28 2022-08-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods, systems, and computer-readable media for predicting a cancer patient's response to immune-based or targeted therapy
JP7438693B2 (ja) 2019-09-02 2024-02-27 キヤノンメディカルシステムズ株式会社 診療支援装置
IL292346B2 (en) 2019-11-05 2025-02-01 Apeel Tech Inc Predicting contamination in plant products
JP2024527371A (ja) * 2021-07-08 2024-07-24 オウロテック インコーポレイテッド 処置の有効性予測システム及び方法
CN115153829B (zh) * 2022-06-23 2026-03-31 中国人民解放军空军军医大学 基于活性组织电阻抗信息非均匀重构的电脉冲消融模型精度优化方法
TWI909458B (zh) * 2024-05-17 2025-12-21 國防醫學大學 一種自體免疫疾病用藥預估方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210867A (en) * 1984-01-31 1989-01-06 Litton Bionetics Inc Tumour-specific monoclonal antibodies, production thereof and use
EP0222360A3 (en) 1985-11-12 1989-03-15 Biotherapeutics Inc. A method of producing a patient-specific cytotoxic reagent and composition
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US6871171B1 (en) * 2000-10-19 2005-03-22 Optimata Ltd. System and methods for optimized drug delivery and progression of diseased and normal cells
WO2002054171A2 (en) * 2000-12-06 2002-07-11 Biosentients, Inc. System, method, software architecture and business model for an intelligent object based information technology platform
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
US8926979B2 (en) * 2005-11-01 2015-01-06 Novartis Ag Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
KR101552735B1 (ko) * 2006-12-01 2015-09-14 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
CN101646470B (zh) * 2007-03-27 2012-08-22 皇家飞利浦电子股份有限公司 基于由加速度传感器测量的患者活动状态的给药
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5734961B2 (ja) * 2009-05-29 2015-06-17 アスペン テクノロジー インコーポレイテッド 多変数プロセス制御においてモデルの品質を推定しモデルを適応させる装置およびその方法
EP2549399A1 (en) * 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
EP2844675B1 (en) * 2012-05-02 2019-01-02 Symphogen A/S Humanized pan-her antibody compositions
CN104470843B (zh) 2012-07-18 2016-07-20 三菱电机株式会社 电梯装置
US9725768B2 (en) * 2012-08-31 2017-08-08 Biovest International, Inc. Methods for producing high-fidelity autologous idiotype vaccines
WO2014126198A1 (ja) * 2013-02-15 2014-08-21 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
ES2662598T3 (es) * 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR
US20160237163A1 (en) * 2013-10-02 2016-08-18 Suri Technologies Ltd. Patient-specific immunotherapy for treating heterogeneous tumors

Similar Documents

Publication Publication Date Title
JP2017502983A5 (https=)
Sanford et al. Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival
Aznar et al. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?
Zindler et al. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery
JP6917357B2 (ja) 癌治療に使用する放射標識抗体断片
Gallamini et al. Interim FDG-PET imaging in lymphoma
JP2020511406A5 (https=)
CN106133521A (zh) 用于治疗异质肿瘤的病患特异性的免疫疗法
Million et al. Radiation therapy for primary cutaneous anaplastic large cell lymphoma: an international lymphoma radiation oncology group multi-institutional experience
JP2021500916A5 (https=)
Ng et al. Individualized 3D reconstruction of normal tissue dose for patients with long-term follow-up: a step toward understanding dose risk for late toxicity
TW201100101A (en) DKK-1 antibodies
AU2018220126A1 (en) Stem cell enhancing therapeutics
Hande et al. Point-A vs. volume-based brachytherapy for the treatment of cervix cancer: A meta-analysis
Jackisch et al. Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival–results from a prospective, observational study in Germany
Telarovic et al. Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumor model
Cannon et al. Metabolic imaging biomarkers of postradiotherapy xerostomia
Rosenberg et al. Survival analyses and prognosis of plasma-cell myeloma and plasmacytoma-like posttransplantation lymphoproliferative disorders
HRP20210858T1 (hr) Antitijelo za igf-1r i njegova upotreba u dijagnosticiranju karcinoma
Wang et al. Validation and comparison of radiograph-based organ dose reconstruction approaches for Wilms tumor radiation treatment plans
Walker et al. Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy
Jacobs Myeloma
Harris et al. Prospective study of patients treated with palliative radiation therapy while on immunotherapy
Cuzzubbo et al. P04. 08 Neurological adverse events associated with the immune checkpoint inhibitors: review of the literature and characterization of the neurological patterns
US20250135231A1 (en) Systems and methods for optimization of radiation treatment planning to improve immune response